James L Gulley

84PUBLICATIONS
328CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (84)

|Sep 14, 2026
Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.

|Sep 12, 2026
Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance.

|Aug 06, 2026
Bi-directional support of T lymphoma and a lymphoma-associated monocyte population involving Notch signaling in mice.

|Jul 24, 2026
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.

|Jul 01, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

|Jun 08, 2026
GPR15-guided CD8+ T regulatory cells control intestinal inflammation.

Pageof 14

Frequent Collaborators

26 joint publications

Jeffrey Schlom

13 joint publications

Ravi A Madan

11 joint publications

Marijo Bilusic

11 joint publications

Renee N Donahue